Nancy L Keating1,2, Gabriel A Brooks3, Mary Beth Landrum1, Pang-Hsiang Liu4, Robert Wolf5, Lauren E Riedel6, Nirav S Kapadia7, Shalini Jhatakia8, Amanda Tripp9, Carol Simon10, Van Doren Hsu11, Colleen M Kummet11, Andrea Hassol12. 1. Department of Health Care Policy, Harvard Medical School, Boston, MA, USA. 2. Division of General Internal Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. 3. Section of Medical Oncology, Department of Medicine, Geisel School of Medicine, Lebanon, NH, USA. 4. Department of Health Care Policy, Harvard Medical School, Boston, MA, USA. 5. Department of Health Care Policy , Harvard Medical School, Boston, MA, USA. 6. Department of Health Care Policy, Harvard Medical School, Boston, MA, USA. 7. Section of Medical Oncology, Department of Medicine, Geisel School of Medicine, Lebanon, NH, USA. 8. The Lewin Group, Falls Church, VA, USA. 9. The Lewin Group, Falls Church, VA, USA. 10. The Lewin Group , Falls Church, VA, USA. 11. General Dynamics Information Technology, Falls Church, VA, USA. 12. Abt Associates, Cambridge, MA, USA.
Abstract
BACKGROUND: Adherence to oral cancer drugs is suboptimal. The Oncology Care Model (OCM) offers oncology practices financial incentives to improve the value of cancer care. We assessed the impact of OCM on adherence to oral cancer therapy for chronic myelogenous leukemia (CML), prostate cancer, and breast cancer. METHODS: Using 2014-2019 Medicare data, we studied chemotherapy episodes for Medicare fee-for-service beneficiaries prescribed tyrosine kinase inhibitors (TKIs) for CML, antiandrogens (ie, enzalutamide, abiraterone) for prostate cancer, or hormonal therapies for breast cancer in OCM-participating and propensity-matched comparison practices. We measured adherence as the proportion of days covered and used difference-in-difference (DID) models to detect changes in adherence over time, adjusting for patient, practice, and market-level characteristics. RESULTS: There was no overall impact of OCM on improved adherence to TKIs for CML (DID = -0.3%, 90% confidence interval [CI] = -1.2% to 0.6%), antiandrogens for prostate cancer (DID = 0.4%, 90% CI = -0.3% to 1.2%), or hormonal therapy for breast cancer (DID = 0.0%, 90% CI = -0.2% to 0.2%). Among episodes for Black beneficiaries in OCM practices, for whom adherence was lower than for White beneficiaries at baseline, we observed small improvements in adherence to high cost TKIs (DID = 3.0%, 90% CI = 0.2% to 5.8%) and antiandrogens (DID = 2.2%, 90% CI = 0.2% to 4.3%). CONCLUSIONS: OCM did not impact adherence to oral cancer therapies for Medicare beneficiaries with CML, prostate cancer, or breast cancer overall but modestly improved adherence to high-cost TKIs and antiandrogens for Black beneficiaries, who had somewhat lower adherence than White beneficiaries at baseline. Patient navigation and financial counseling are potential mechanisms for improvement among Black beneficiaries.
BACKGROUND: Adherence to oral cancer drugs is suboptimal. The Oncology Care Model (OCM) offers oncology practices financial incentives to improve the value of cancer care. We assessed the impact of OCM on adherence to oral cancer therapy for chronic myelogenous leukemia (CML), prostate cancer, and breast cancer. METHODS: Using 2014-2019 Medicare data, we studied chemotherapy episodes for Medicare fee-for-service beneficiaries prescribed tyrosine kinase inhibitors (TKIs) for CML, antiandrogens (ie, enzalutamide, abiraterone) for prostate cancer, or hormonal therapies for breast cancer in OCM-participating and propensity-matched comparison practices. We measured adherence as the proportion of days covered and used difference-in-difference (DID) models to detect changes in adherence over time, adjusting for patient, practice, and market-level characteristics. RESULTS: There was no overall impact of OCM on improved adherence to TKIs for CML (DID = -0.3%, 90% confidence interval [CI] = -1.2% to 0.6%), antiandrogens for prostate cancer (DID = 0.4%, 90% CI = -0.3% to 1.2%), or hormonal therapy for breast cancer (DID = 0.0%, 90% CI = -0.2% to 0.2%). Among episodes for Black beneficiaries in OCM practices, for whom adherence was lower than for White beneficiaries at baseline, we observed small improvements in adherence to high cost TKIs (DID = 3.0%, 90% CI = 0.2% to 5.8%) and antiandrogens (DID = 2.2%, 90% CI = 0.2% to 4.3%). CONCLUSIONS: OCM did not impact adherence to oral cancer therapies for Medicare beneficiaries with CML, prostate cancer, or breast cancer overall but modestly improved adherence to high-cost TKIs and antiandrogens for Black beneficiaries, who had somewhat lower adherence than White beneficiaries at baseline. Patient navigation and financial counseling are potential mechanisms for improvement among Black beneficiaries.
Authors: Carlo Gambacorti-Passerini; Laura Antolini; François-Xavier Mahon; Francois Guilhot; Michael Deininger; Carmen Fava; Arnon Nagler; Chiara Maria Della Casa; Enrica Morra; Elisabetta Abruzzese; Anna D'Emilio; Fabio Stagno; Philipp le Coutre; Rafael Hurtado-Monroy; Valeria Santini; Bruno Martino; Fabrizio Pane; Andrea Piccin; Pilar Giraldo; Sarit Assouline; Muheez A Durosinmi; Onno Leeksma; Enrico Maria Pogliani; Miriam Puttini; Eunjung Jang; Josy Reiffers; Maria Grazia Valsecchi; Dong-Wook Kim Journal: J Natl Cancer Inst Date: 2011-03-21 Impact factor: 13.506
Authors: Nancy L Keating; Shalini Jhatakia; Gabriel A Brooks; Amanda S Tripp; Inna Cintina; Mary Beth Landrum; Qing Zheng; Thomas J Christian; Roberta Glass; Van Doren Hsu; Colleen M Kummet; Susannah Woodman; Carol Simon; Andrea Hassol Journal: JAMA Date: 2021-11-09 Impact factor: 56.272
Authors: Thomas G Knight; Allison M Deal; Stacie B Dusetzina; Hyman B Muss; Seul Ki Choi; Jeannette T Bensen; Grant R Williams Journal: J Oncol Pract Date: 2018-10-24 Impact factor: 3.840
Authors: Stacie B Dusetzina; Aaron N Winn; Gregory A Abel; Haiden A Huskamp; Nancy L Keating Journal: J Clin Oncol Date: 2013-12-23 Impact factor: 44.544
Authors: Stephanie B Wheeler; Jennifer Spencer; Laura C Pinheiro; Caitlin C Murphy; Jo Anne Earp; Lisa Carey; Andrew Olshan; Chiu Kit Tse; Mary E Bell; Morris Weinberger; Katherine E Reeder-Hayes Journal: J Natl Cancer Inst Date: 2019-05-01 Impact factor: 13.506
Authors: Megan E V Caram; Mary K Oerline; Stacie Dusetzina; Lindsey A Herrel; Parth K Modi; Samuel R Kaufman; Ted A Skolarus; Brent K Hollenbeck; Vahakn Shahinian Journal: Cancer Date: 2020-09-14 Impact factor: 6.860